Isoacteoside

Isoacteoside is a natural product that can significantly inhibit the formation of glycation end products. Isoacteoside regulates the AKT/PI3K/m-TOR/NF-κB signaling pathway, induces apoptosis in OVCAR-3 cell. Isoacteoside exhibits antitumor, anti-inflammatory, anti-obesity and neuroprotective activities^{[1][2][3][4][5]}. In Vitro:Isoacteoside (20-80 μM, 24 h) inhibits the expression of iNOS and COX-2 in RAW264.7, inhibits LPS (HY-D1056)-induced release of TNF-α, IL-6, and IL-1β, as well as the activation of NF-κB^[2].
Isoacteoside (15-30 μM, 24-48 h) inhibits the proliferation, invasion and migration of cancer cell OVCAR-3 (IC₅₀=15 μM), arrests the cell cycle at sub-G1 phase, and induces the generation of ROS^[3].
Isoacteoside (15-30 μM, 48 h) inhibits the phosphorylation of AKT, mTOR, p38 MAPK, and PI3K without affecting their total protein expression^[2][3].
Isoacteoside (75-150 μM, 24-48 h) reduces the formation of lipid droplets and inhibits the expression of genes and proteins related to adipogenesis and lipid synthesis^[4].
In Vivo:Isoacteoside (25-100 mg/kg, ip, single dose) exhibits anti-inflammatory efficacy in mouse xylene-induced ear edema models, LPS (HY-D1056)-induced endotoxin shock models, and LPS (HY-D1056)-induced acute kidney injury (AKI) models^[2].
Isoacteoside (30 mg/kg, ip, three times a week for 5 weeks) exhibits antitumor efficacy in mouse OVCAR-3 xenograft models^[3].
Isoacteoside (2.5-5 mg/kg, icv for 15 days) exhibits neuroprotective effect against Aβ 1-42-induced neurotoxicity and cognitive impairment in SD rats models^[5].